A Weibull multi‐state model for the dependence of progression‐free survival and overall survival-Reference-Cited by-同舟云学术

A Weibull multi‐state model for the dependence of progression‐free survival and overall survival

Published:2015-04-10 Issue:17 Volume:34 Page:2497-2513
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statist. Med.

Author:

Li Yimei¹²^ORCID,Zhang Qiang¹³

Affiliation:

1. Department of Biostatistics and Epidemiology University of Pennsylvania Perelman School of Medicine Philadelphia U.S.A.

2. The Children's Hospital of Philadelphia Philadelphia U.S.A.

3. Radiation Therapy Oncology Group (RTOG) American College of Radiology Philadelphia U.S.A.

Funder

Pennsylvania Department of Health

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/sim.6501

Reference16 articles.

1. U.S. Department of Health and Huamn Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics2007.

2. In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer

3. Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials

4. Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments

5. Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bayesian survival extrapolation for cost-effectiveness analysis: a case study of RELAY for ramucirumab in combination with erlotinib in the treatment of non-small-cell lung cancer;Journal of Medical Economics;2023-11-30

2. Interval-Censored Regression with Non-Proportional Hazards with Applications;Stats;2023-05-17

3. From Logic-Respecting Efficacy Estimands to Logic-Ensuring Analysis Principle for Time-to-Event Endpoint in Randomized Clinical Trials with Subgroups;Statistics in Biopharmaceutical Research;2023-04-18

4. Complex survival trial design by the product integration method;Statistics in Medicine;2021-12-15

5. Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer;Clinical Therapeutics;2021-06